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ABSTRACT: Previous studies have established that 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine is
an efficient time- and concentration-dependent inhibitor of the flavin-containing enzyme monoamine oxidase
B (MAO-B). This behavior is consistent with a proposed mechanism-based inactivation pathway which
proceeds via an initial single electron transfer step to generate an unstable cyclopropylaminyl radical
cation intermediate that alkylates an active site functionality via the ring opened primary carbon centered
radical. More recently we have found that, in addition to being an inhibitor, the corresponding
1-cyclopropyl-4-benzyl-1,2,3,6-tetrahydropyridine species is an excellent MAO-B substrate, behavior which
may not be consistent with the obligatory formation of a cyclopropylaminyl radical cation intermediate.
In an attempt to gain further insight into the mechanism associated with the MAO catalyzed oxidation of
1,4-disubstituted tetrahydropyridines, we have undertaken deuterium isotope effect studies on the substrate
and inhibitor properties of this 4-benzyl-1-cyclopropyltetrahydropyridine derivative. A normal isotope
effect was observed on kcat/KM. Although the good substrate properties of this compound prevented an
accurate estimate of kinact and KI, we did observe a very modest inverse isotope effect on the rate of
inactivation of 0.1 µM MAO-B by 500 µM inactivator. The results are discussed in terms of possible
mechanisms for the MAO-B catalyzed oxidation of 1,4-disubstituted 1,2,3,6-tetrahyrdopyridines.
The discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP,1 1) causes the selective destruction of
nigrostriatal neurons leading to a Parkinsonian syndrome in
humans has stimulated interest in delineating the mechanism
of action of this neurotoxin (Langston, 1989). Previous
studies have established that the neurotoxicity of MPTP is
mediated by the corresponding pyridinium species MPP+ (3)
which is generated via the dihydropyridinium intermediate
MPDP+ (2) in a reaction sequence catalyzed by monoamine
oxidase B (MAO-B) and, less efficiently, by MAO-A as
illustrated in Scheme 1 (Chiba et al., 1984; Salach et al.,
1984). The excellent MAO-B substrate properties of MPTP
were unexpected since previously no cyclic tertiary amines
had been shown to be substrates for this enzyme. These
characteristics of MPTP have prompted us (Kalgutkar et al.,
1994; Zhao et al., 1992; Kalgutkar & Castagnoli, 1992) and
others (Efange et al., 1993; Krueger et al., 1992; Youngster
et al., 1989) to explore the special structural features of 1,4-
disubstituted 1,2,3,6-tetrahydropyridines that are responsible
for their unique MAO substrate properties.
One proposed mechanism for the MAO-catalyzed R-car-
bon oxidative deamination of amines that has been studied
extensively proceeds by an initial single electron transfer
(SET) step from the nitrogen lone pair of the substrate (4)
to the oxidized flavin (FAD) to generate an aminyl radical
cation (5) and the flavin radical FADH• (Scheme 2).
R-Carbon deprotonation of 5 yields the carbon-centered
radical 6 which undergoes a second one-electron oxidation
to form the iminium product 7 and the fully reduced flavin
(FADH2). Subsequent hydrolysis of 7 provides the deami-
nated product 8 (Silverman, 1991, 1995b). This SET
mechanism is supported by results from studies on mecha-
nism-based MAO-B inactivators such as N-benzylcyclopro-
pylamine (9) and model photochemical (Kim et al., 1991)
and ESR (Yelekci et al., 1989) studies. The putative
cyclopropylaminyl radical cation 10 generated by the SET
pathway (Scheme 3) is proposed to undergo rapid ring
opening to form the highly reactive primary radical 11 which
mediates the inactivation of the enzyme (Silverman &
Yamasaki, 1984; Silverman & Zieske, 1985, 1986). Ad-
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Scheme 1. MAO-B Catalyzed Oxidation of MPTP (1)
Scheme 2. Proposed Pathways for the MAO-Catalyzed
Oxidation of Amines
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ditional evidence considered to be consistent with this
mechanism is the similarity observed in the isotope effects
on kcat/KM and kinact/KI for milacemide (Silverman et al.,
1993).
We have found that 1-cyclopropyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (12) is a good time- and concentration-
dependent inhibitor of MAO-B (Hall et al., 1992). This
behavior is consistent with a radical reaction pathway
(Scheme 4) analogous to that proposed by Silverman for
N-benzylcyclopropylamine (Scheme 2). Initial one-electron
transfer from 12 to FAD would generate the cyclopropy-
laminyl radical cation 13. This intermediate would have the
option to ring open to the reactive primary radical 14
(pathway a leading to enzyme inactivation) or to lose an
R-proton (pathway b) to yield the resonance stabilized allylic
radical 15a T 15b which subsequently would undergo a
second one-electron loss to generate the dihydropyridinium
intermediate 16. Since the dihydropyridinium metabolite was
not detected under conditions leading to enzyme inactivation,
one may conclude that the rate of ring opening must be much
faster than the rate of R-proton loss as would be anticipated
by the very rapid ring opening rates reported for cyclopro-
pylcarbinyl (Atkinson & Ingold, 1993; Martin-Esker et al.,
1994) and cyclopropylaminyl (Maeda & Ingold, 1980)
radicals.
More recently, we examined the interactions of 4-benzyl-
1-cyclopropyl-1,2,3,6-tetrahydropyridine (17) with MAO-B
(Kuttab et al., 1994). The corresponding N-methyl analog
18 (see Scheme 1) is a better MAO-B substrate than is MPTP
(Naiman et al., 1990), and therefore we anticipated that 17
would display more potent inactivator properties. Although
17 proved to be a time- and concentration-dependent inhibitor
of MAO-B, it unexpectedly displayed excellent MAO-B
substrate properties. According to the SET mechanism, the
intermediate cyclopropylaminyl radical cation 19 must parti-
tion between pathway a, leading to the primary carbon
centered radical 20 and enzyme inactivation, and pathway
b, leading to the allylic radical intermediate 21a T 21b and
product (22) formation (Scheme 4). Rough estimates of the
partition ratio between these two pathways suggested that
over 1000 substrate molecules should be converted to product
for each molecule of enzyme that undergoes inactivation.
These considerations argue either that opening of the
cyclopropyl ring of the radical cation 19 is slower than proton
loss at C-6 or that formation of 22 does not proceed via 19.
In an attempt to gain additional insight into the interactions
of 17 with MAO-B, we have examined the deuterium isotope
effects on the rates of substrate turnover and enzyme
inhibition. The studies were carried out with 4-benzyl-1-
cyclopropyl-1,2,3,6-tetrahydropyridine-2,2,6,6-d4 (17-d4) and
a purified form of MAO-B isolated from beef liver.
EXPERIMENTAL PROCEDURES
Chemistry. CAUTION: 1-Methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (1) is a known nigrostriatal neurotoxin and
should be handled using disposable gloves in a properly
ventilated hood. Detailed procedures for the safe handling
of MPTP have been reported (Pitts et al., 1986).
Synthetic reactions were carried out under a nitrogen
atmosphere. R-(-)- deprenyl was obtained from Research
Biochemicals Inc., Natic, MA. All other chemicals (Aldrich,
Milwaukee, WI) were reagent or HPLC grade. Proton NMR
spectra were recorded on a Bruker WP 270-MHz spectrom-
eter. Chemical shifts (δ) are reported in parts per million
(ppm) relative to tetramethylsilane as internal standard. Spin
multiplicities are given as s (singlet), d (doublet), t (triplet),
or m (multiplet). Gas chromatography/electron ionization
mass spectrometry (GC/EIMS) was performed under electron
ionization conditions using a Hewlett Packard (HP) 5890
capillary GC equipped with an HP-1 capillary column (12-m
× 200-mm× 0.33-mm film thickness) coupled to a HP 5970
mass-selective detector. Data were acquired using a HP 5970
MS ChemStation. Normalized peak heights are reported as
percentage of the base peak. Melting points were obtained
on a Thomas-Hoover melting point apparatus and are
uncorrected.
Methyl Acrylate-2,2-d2 (24). A mixture of anhydrous
DMSO (60 mL) and NaH (2.32 g of 60% oil dispersion, 58
mmol) was stirred under N2 at 65 °C until a clear solution
resulted. To this solution was added portionwise (1 h) with
stirring at room temperature 24 g (58 mmol) of methoxy-
carbonylmethyltriphenylphosphonium bromide [23, mp 167-
168 °C; lit. (Ayrey & Wong, 1978) mp 162-163 °C] to
generate the Wittig reagent. Solid paraformaldehyde-d2 (2
g, 63 mmol) was cracked in a separate flask at 200 °C, and
the resulting vapors were condensed in the reaction flask,
maintained at 90 °C, that contained the above Wittig reagent.
The reaction mixture was stirred and maintained at 90 °C
for 2 h and then stirred overnight at room temperature. The
product (2.66 g, 53%) was obtained by vacuum distillation
(50 torr) with the receiver cooled to -78 °C: 1H NMR
(CDCl3) δ 6.12 (s, CH, 1H), 3.76 (s, OCH3, 3H).
Oxalate Salt of 1-Cyclopropyl-4-benzyl-1,2,3,6-tetrahy-
dropyridine-2,2,6,6-d4 (17-d4). Synthesis of the desired
2,2,6,6-tetradeutero analog 17-d4 was achieved by following
the literature procedure for the d0-compound 17-d0 (Kuttab
et al., 1994). The physicochemical characteristics of the final
product and the intermediate species are summarized below.
N,N-Bismethoxycarbonylmethylcyclopropylamine-d4. Yel-
low oil, (89%); bp 114-115 °C/50 Torr; 1H NMR (CDCl3)
δ 3.66 (s, OCH3, 6H), 2.50 (s, NCD2CH2, 4H), 2.15 (m,
NCHCH2, 1H), 0.40 (m, NCHCH2, 4H); GC/EIMS (tem-
perature program, 125 °C for 1 min followed by a ramp of
10 °C/min for 10 min) showed a single peak with tR ) 3.17
min and m/z 233 (M•+, 12), 174 (30), 160 (100), 89 (34), 59
(48).
1-Cyclopropyl-4-piperidone-2,2,6,6-d4. Yellow oil (51%);
1H NMR (CDCl3) δ 2.41 (s, NCD2CH2, 4H), 1.78 (m,
NCHCH2, 1H), 0.53 (m, NCHCH2, 4H); GC/EIMS (tem-
perature program, 80 °C for 2 min followed by a ramp of
10 °C/min for 15 min) showed a single peak with tR ) 4.44
min and m/z 143 (M•+, 20), 100 (40), 99 (80), 85 (62), 70
(100), 55 (78).
4-Benzyl-1-cyclopropyl-4-piperidinol-d4. Yellow oil (77%);
GC/EIMS (temperature program, 125 °C for 1 min followed
by a ramp of 10 °C/min for 10 min) showed a single peak
with tR ) 4.774 min and m/z 235 (M•+, 38), 205 (42), 144
(40), 101 (65), 85 (100), 72 (78).
Scheme 3. Proposed MAO-B Catalyzed SET Pathway for
N-Benzylcyclopropylamine (9) Leading to the Primary
Carbon Radical 11
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Oxalate Salt of 1-Cyclopropyl-4-benzyl-1,2,3,6-tetrahy-
dropyridine-d4 (17-d4). Mp 144-145 °C [17-d0 lit. (Kuttab
et al., 1994) mp 148-149 °C]; 1H NMR (DMSO-d6) δ 7.1-
7.4 (m, ArH, 5H), 5.45 (bs, NCD2CH, 1H), 3.31 (s, ArCH2,
2H), 2.49 (m, NCHCH2, 1H), 2.10 (s, NCD2CH2, 2H), 0.6-
0.8(m, NCHCH2, 4H); GC/EIMS (temperature program, 125
°C for 1 min followed by a ramp of 10 °C/min for 8 min)
showed a single peak with tR ) 4.14 min and m/z 217 (M•+,
65), 201 (100), 91 (55), 70 (40).
Enzymology. The isolation and purification of MAO-B
from beef liver was carried out using the methodology
reported earlier (Salach & Weyler, 1987) with the following
variations. The phospholipase A used in our preparation was
obtained commercially (Sigma, St. Louis, MO) rather than
from the crude venom, and we did not subject the preparation
to the sucrose gradient purification step. We obtained a
highly active and stable preparation which was stored at -15
°C in 200-400 µL aliquots. A 0.09 µM solution of the
enzyme was transparent in the UV range of interest. The
specific activity was determined spectrophotometrically at
30 °C on a Beckman DU-50 spectrophotometer by estimating
the initial (30-120 s) rates of conversion of 5 mM MPTP
(1) to the dihydropyridinium species 2 (λmax ) 343 nm, ²
)16 000 M-1, kcat ) 204 min-1) as described previously
(Kalgutkar et al., 1994). The final enzyme concentration
was calculated to be 9.0 nmol/mL.
All enzyme assays were performed in triplicate at 37 °C
with a Beckman DU-50 spectrophotometer. The MAO-B
substrate properties of 17-d0 and 17-d4 were examined
following published procedures (Kalgutkar et al., 1994). The
molar extinction coefficient of the corresponding dihydro-
pyridinium species was taken to be 5530 M-1, corresponding
to 4-benzyl-1-methyl-2,3-dihydropyridinium perchlorate
(Naiman et al., 1990).
The MAO-B inactivation properties of 17-d0 and 17-d4
were examined following published procedures (Rimoldi et
al., 1995). A substrate protection experiment was performed
with benzylamine and 17-d0. A mixture of MAO-B (0.8
µM), 17-d0 (0.4 mM), and benzylamine (2 mM) was gently
agitated in a water bath incubated at 37 °C. Aliquots (25
µL) removed at 0, 4, 8, and 12 min were assayed for
remaining enzyme activity using 5 mM MPTP (475 µL) as
described previously (Hall et al., 1992).
Determination of the Partition Ratio for 17-d0 and 17-d4.
A 0.5 mL mixture of MAO-B (0.09 µM) and 17-d0 or 17-d4
(0.5 mM) was allowed to incubate at 37 °C for 1 min during
which time dihydropyridinium product 22-d0 or 22-d3 forma-
tion was recorded spectrophotometrically at 296 nm. Identi-
cal 1 min incubation mixtures were assayed for remaining
enzyme activity by adding an equal volume of 10 mMMPTP
and determining the rate of MPDP+ formation as usually
performed in our inactivation studies. The ratio of nmol of
product formed per nmol of enzyme inactivated was calcu-
lated from these measurements, and the corresponding
deuterium isotope effect on the partition ratio was obtained
from the partition ratios for 17-d0 and 17-d4.
GC/EIMS Assay for 17-d0. A 500 µL mixture containing
0.5 mM 17-d0 and 4.5 µM MAO-B was incubated at 37 °C.
Aliquots (20 µL) removed at 0, 2, 4, 6, and 8 min were added
to 480 µL of 10% aqueous K2CO3 maintained at 0 °C. The
resulting basic solution was extracted with ethyl acetate (1
mL) and the organic layer was dried over MgSO4. A 1 µL
sample was analyzed by GC-EIMS selected ion monitoring
at m/z 213 (temperature program: 125 °C for 1 min followed
by a ramp of 25 °C/min for 5 min and then a ramp of 50
°C/min to 300 °C). In a control experiment, MAO-B was
preincubated with 10 µM deprenyl for 10 min at 37 °C and
then treated as above.
Determination of the IrreVersibility of the InactiVation of
MAO-B by 17-d0. A 200 µL mixture containing 2.3 µM
MAO-B and 0.5 mM 17-d0 in 100 mM sodium phosphate
buffer pH 7.4 was incubated at 37 °C for 3 h. After adding
100 µL of 0.3% Blue Dextran solution in the same buffer
the solution was applied to Sephadex G-25 (1.5 × 6 cm)
previously equilibrated with 100 mM sodium phosphate
buffer, pH 7.4, and eluted with the same buffer at a flow
rate of 1.0 mL/min. The fraction containing the majority of
the Blue Dextran was collected and assayed for enzyme
activity using 5 mM MPTP. In a control experiment, 2.3
µM MAO-B was incubated with buffer for 3 h at 37 °C,
and the procedure was repeated as above.
RESULTS
Chemistry. The synthesis of 4-benzyl-1-cyclopropyl-
1,2,3,6-tetrahydropyridine-2,2,6,6-d4 (17-d4) followed the
reported synthesis of the d0 compound (17-d0) (Kuttab et
al., 1994). The key deuterated starting material, methyl
acrylate-d2, was prepared via a Wittig reaction following a
literature procedure for the synthesis of methyl methacrylate-
d2 (Ayrey & Wong, 1978).
Scheme 4. Proposed SET Pathway for the MAO-B Catalyzed Oxidation of 1-Cyclopropyltetrahydropyridine Derivatives 12 and
17
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Enzymology. The kinetic deuterium isotope effects on kcat
and KM for the MAO-B catalyzed oxidation of 17-d0 and
17-d4 were estimated by measuring the rates of formation
of the corresponding dihydropyridinium metabolites 22-d0
and 22-d3 spectrophotometrically over a substrate concentra-
tion range of 150-1000 µM in the presence of a fixed
concentration (0.1 µM) of MAO-B. At the higher substrate
concentrations the plots of time vs concentration of dihy-
dropyridinium metabolites were curvilinear. Since only a
small percentage of the substrate would have been consumed
in these experiments during the 2 min data collection periods,
the slowing down of the rate of product formation was
assumed to be a consequence of the inactivation of the
enzyme. Despite this problem, the double reciprocal plots
generated from these rate data gave straight lines (r2 > 0.97)
for both the d0 and the d4 substrates. The kcat and KM values
estimated for the d0 substrate (810 ( 78 min-1 and 0.40 (
0.08 mM, respectively) compared well with the correspond-
ing values (637 min-1 and 0.40 mM) reported by us
previously (Kuttab et al., 1994) The corresponding analyses
for 17-d4 gave values of 530 ( 65 min-1 for kcat and 0.37 (
0.07 mM for KM. Based on these data, the deuterium kinetic
isotope effect on kcat/KM is 1.4 and on kcat 1.5. This
intermolecular isotope effect argues that cleavage of the
allylic carbon-hydrogen bond is at least partially rate
determining in the MAO-B catalyzed oxidation of 17 to the
corresponding dihydropyridinium metabolite 22.
The previously observed concentration- and time-depend-
ent MAO-B inhibition properties of 17 were interpreted as
being consistent with a mechanism-based inactivation path-
way (Silverman, 1988). Additional evidence to support this
tentative conclusion now has been obtained. As expected,
the preferred MAO-B substrate benzylamine (2 mM) pro-
tected against loss of enzyme activity mediated by 17-d0 (500
µM). After an 8 min incubation period only 10% of the
original activity remained in the absence of benzylamine
while 68% remained in the presence of benzylamine. We
also examined the reversibility of the inhibition. MAO-B
(2.3 µM) was completely inhibited following incubation with
17-d0 (500 µM) for 180 min. The enzyme recovered
following passage through Sephadex G-25 showed no
recovery of activity. In a control experiment (buffer only)
over 90% of the original activity was recovered. Conse-
quently, it is reasonable to assume that 17 is a classical
mechanism-based inactivator that inhibits MAO-B through
covalent bond formation between an enzyme generated
reactive species and an active site functionality.
The inactivation curve observed in the above experiment
showed biphasic kinetic behavior with the initial, rapid phase
having a kobs ) 0.06 min-1 and the second, slow phase with
kobs ) 0.005 min-1. Consequently, it appeared that product
inhibition also was contributing to the loss of enzyme
activity. This conclusion was confirmed by actual measure-
ments of remaining substrate vs time of a typical incubation
(500 µM 17-d0 and 4.5 µM MAO-B) used in our attempts
to estimate kinact and KI (see below). Quantitative GCMS
analysis of this incubation mixture showed that the remaining
concentration of 17-d0 after a 2 min incubation period was
only 2 µM, a substrate concentration which would show no
detectable enzyme inhibition at these enzyme concentrations.
On the other hand, 54 ( 8% (average of four experiments)
of the enzyme activity was still present at this time. The
remaining enzyme activity, however, continued to decline
slowly, presumably via an enzyme generated metabolite,
possibly the dihydropyridinium species 22. Since no enzyme
activity is recoverable following Sephadex chromatography,
both types of inactivation must be irreversible. Although
we have not been able to synthesize 22 to perform kinetic
studies, inactivation properties have been observed with the
MAO-B generated dihydropyridinium metabolite 2 derived
from MPTP (Singer et al., 1986).
Previous attempts to estimate kinact and KI for the inactiva-
tion of 4.5 µMMAO-B by 17 in which the reaction mixture
was sampled every 4 min displayed non-pseudo-first-order
kinetics (Silverman, 1995a), presumably because of the high
partition ratio and the associated rapid consumption of the
inactivator. We have made an additional attempt to collect
useful inactivation kinetic data by sampling the incubation
mixture for remaining enzyme activity every 1 min. Even
under these conditions, however, the kinetics of inactivation
still did not follow Michaelis-Menton behavior, i.e., the
double-reciprocal plot of kobs vs inhibitor concentration gave
an X-intercept greater than zero. Due to the limited solubility
properties of 17, we were not able to examine a greater
concentration range which might have provided more reliable
data.
In an effort to obtain a useful estimate of the influence of
deuterium substitution on the relative rates at which 17-d0
and 17-d4 inactivate MAO-B, we determined the nanomoles
of enzyme inactivated at 1 min in an incubation mixture
containing 500 µM 17-d0 or 17-d4 and 0.1 µMMAO-B, that
is, under incubation conditions in which less than 10% of
the substrate would be consumed at the time of the
measurement. The experiment was ran in triplicate and gave
values of 32.0 ( 0.6 × 10-3 nmol of MAO-B inactivated/
(mL‚min) for 17-d0 and 35.0 ( 1.9 × 10-3 nmol of MAO-B
inactivated/(mL‚min) for 17-d4. From these data an isotope
effect of 0.92 (0.85-0.98) was calculated for the rate of
inactivation of 0.1 µM MAO-B by 500 µM 17. The rates
of substrate turnover under the same conditions gave values
of 40.0 ( 2.5 nmol of dihydropyridinium formed/(mL‚min)
for 17-d0 and 28.0 ( 1.7 nmol of dihydropyridinium formed/
(mL‚min) for 17-d4. The corresponding partition ratios are
1250 (17-d0) and 800 (17-d4) nmol of dihydropyridinium
formed/nmol of MAO-B inactivated, and the isotope effect
on the partition ratio is 1.6.
DISCUSSION
Initial electron transfer vs hydrogen atom transfer in
enzyme-catalyzed oxidations of amines has been a topic of
debate. Although the SET pathway has enjoyed much favor,
it also has been challenged. Results from rapid-scan stopped
flow and magnetic field effect studies on the MAO-B
catalyzed oxidation of [R,R-2H]benzylamine have led Ed-
mondson to argue against the SET pathway since he could
find no evidence of the formation of a flavin radical pair
intermediate in this reaction (Miller et al., 1995). Edmond-
son also has suggested that single-electron transfer from an
amine to the flavin is thermodynamically and kinetically
improbable since the energy barrier for electron transfer is
greater than the energy barrier for the reduction of FAD to
FADH2 (Walker & Edmondson, 1994). A similar debate
concerns the cytochrome P450 catalyzed oxidations of
tertiary amines (Hanzlik & Tullman, 1982; Guengerich &
Macdonald, 1984; Miwa et al., 1983; Karki et al., 1995;
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Carlson et al., 1995). Energy estimates derived from
chemical models and the enzyme-catalyzed oxidation of N,N-
dimethylaniline derivatives again suggest that, even in polar
solvents that might stabilize the radical cation, hydrogen atom
transfer is energetically preferred over the SET pathway by
several kcal/mol (Dinnocenzo et al., 1993). Similar conclu-
sions based on isotope effects and stereochemical arguments
have been reached in the case of the cytochrome P450-
catalyzed R-carbon oxidation of (S)-nicotine (Carlson et al.,
1995).
The unexpected substrate properties of 17 have prompted
us to consider the possibility that the cyclopropylaminyl
radical cation also may not be an obligatory intermediate in
the MAO-B catalytic pathway of these tetrahydropyridine
derivatives. Opening of the cyclopropyl ring via a confor-
mation which allows overlap of the half filled p-orbital of
the radical cation with the p-like orbitals of the cyclopropyl
carbon-carbon bonds is considered to be an energetically
favored process because of the release of ring strain
(Silverman, 1995b). Nevertheless, conformational con-
straints imposed by the active site on the conformation of
the tetrahydropyridine substrate could restrict orbital align-
ments in which case an alternative reaction, proceeding
through an active site base promoted deprotonation at the
allylic C-6 position, might compete kinetically with the ring
opening reaction. In this case, formation of the dihydropy-
ridinium product could dominate the reaction as, in fact, is
observed with the MAO-B catalyzed oxidation of 17. On
the other hand, one also could account for the observed
substrate and inactivation properties of 17 if partitioning were
to occur between an electron transfer pathway and a pathway
proceeding via direct carbon-hydrogen bond cleavage.
Fitzpatrick and Villafranca (1986) have proposed such a
partitioning for mixed substrate/inactivators of dopamine
â-hydroxylase such as benzylhydrazine. These investigators
report that the observed normal deuterium isotope effect on
the partition ratio, the inverse deuterium isotope effect on
kinact/KI, and the normal deuterium isotope effect on Vmax are
most consistent with a partitioning that occurs at the point
of C-H bond cleavage and that this bond cleavage is
involved only in product formation and not in inactivation.
Although we have not been able to obtain kinact and KI
values, the results of our kinetic studies suggest a weak
inverse isotope on the inactivation of MAO-B by 17 and a
normal isotope effect on product formation and the partition
ratio, behavior that is analogous to the kinetic pattern reported
by Fitzpatrick and Villafranca. Consequently, although
partitioning following electron transfer cannot be ruled out,
we interpret the results reported here as consistent with a
pathway involving the partitioning of 17 between the single-
electron transfer product 19 and the hydrogen atom transfer
product 21 (Scheme 5). Such a process presumably would
involve the participation of a protein derived radical species
(Enz-X•) that would generate the allylic radical intermediate
21. One-electron oxidation of 21 by FAD would result in
product 22 formation. Finally, the enzyme-bound radical
would be regenerated in a reaction coupled to the reduction
of FADH• to FADH2. An inverse isotope effect on inactiva-
tion would be expected since the normal isotope effect on
hydrogen atom abstraction would increase the probability
of the one-electron oxidation of 17 to 19. This pathway is
attractive in that it obviates the need to invoke a kinetic
preference for proton loss over ring opening of a cyclopro-
pylaminyl radical cation and is consistent with the direct
formation of a highly resonance stabilized (by the nitrogen
lone pair and the styryl system) carbon radical.
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